AGHEMO, Alessio Michele Goffredo
 Distribuzione geografica
Continente #
NA - Nord America 7819
EU - Europa 1102
AF - Africa 277
AS - Asia 152
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 7
SA - Sud America 4
Totale 9368
Nazione #
US - Stati Uniti d'America 7726
FI - Finlandia 275
NG - Nigeria 273
FR - Francia 150
DE - Germania 116
IT - Italia 108
NL - Olanda 100
SE - Svezia 94
CA - Canada 92
IE - Irlanda 71
BE - Belgio 58
GB - Regno Unito 57
IL - Israele 42
TR - Turchia 40
IN - India 16
IR - Iran 14
RU - Federazione Russa 13
RO - Romania 9
UA - Ucraina 9
HK - Hong Kong 8
MK - Macedonia 8
SG - Singapore 8
ES - Italia 7
A2 - ???statistics.table.value.countryCode.A2??? 6
AU - Australia 6
GR - Grecia 6
PH - Filippine 5
CH - Svizzera 4
CN - Cina 4
JP - Giappone 4
CL - Cile 3
EG - Egitto 3
MD - Moldavia 3
NO - Norvegia 3
PK - Pakistan 3
TW - Taiwan 3
AL - Albania 2
BD - Bangladesh 2
BG - Bulgaria 2
PL - Polonia 2
SA - Arabia Saudita 2
AT - Austria 1
BR - Brasile 1
DK - Danimarca 1
EU - Europa 1
ID - Indonesia 1
IM - Isola di Man 1
IS - Islanda 1
NZ - Nuova Zelanda 1
PA - Panama 1
RS - Serbia 1
UG - Uganda 1
Totale 9368
Città #
Chandler 1932
Wilmington 1653
San Mateo 692
Ann Arbor 530
Leawood 311
Lawrence 289
Princeton 289
Helsinki 275
Benin City 273
Paris 150
Woodbridge 136
Fairfield 133
Boardman 113
Amsterdam 99
Toronto 87
Dublin 71
Brussels 58
Seattle 53
London 51
San Diego 49
Milan 43
Kocaeli 39
Norwalk 34
Falls Church 27
Cambridge 15
Monmouth Junction 15
Des Moines 11
Redmond 11
Redwood City 11
Andover 10
Clearwater 10
Frankfurt am Main 9
Hanover 9
Houston 8
Falkenstein 7
Ardabil 6
Ashburn 6
Sacramento 6
Abbiategrasso 5
Berlin 5
Bitola 5
Henderson 5
Gunzenhausen 4
Singapore 4
Winnipeg 4
Chisinau 3
Dallas 3
Santa Clara 3
Skopje 3
Taipei 3
Adliswil 2
Apo 2
Athens 2
Beijing 2
Cairo 2
Florence 2
Genoa 2
Hangzhou 2
Kemerovo 2
Las Pinas 2
Las Vegas 2
Leipzig 2
Los Angeles 2
Manila 2
Monza 2
Novokuznetsk 2
Penrith 2
Phoenix 2
Raleigh 2
Reghin 2
St Petersburg 2
Tonara 2
Torino 2
Aachen 1
Al Mansurah 1
Alexandria 1
Augusta 1
Bari 1
Belgrade 1
Bussolengo 1
Cagayan de Oro 1
Canberra 1
Caponago 1
Central District 1
Chicago 1
Citta 1
Crema 1
Cupertino 1
Denver 1
Douglas 1
Eden Prairie 1
Esslingen am Neckar 1
Iasi 1
Islamabad 1
Jakarta 1
Karachi 1
Kharkov 1
La Canada Flintridge 1
Lahore 1
Madrid 1
Totale 7641
Nome #
12 weeks ombitasvir/paritaprevir-ritonavir plus ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis 71
Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study 66
A 13-day, interferon-free regimen for chronic hepatitis C genotype 1 patients: between fear and hope. 65
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection 62
Real life experiences in HCV management in 2018 58
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 54
Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis 53
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population 51
The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies 51
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 51
Impact of chronic exposure to 5-alpha reductase inhibitors on the risk of hospitalization for COVID-19: a case-control study in male population from two COVID-19 regional centers of Lombardy (Italy) 51
Daclatasvir : a team player rather than a prima donna in the treatment of hepatitis C 50
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 50
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent 50
Pegylated IFN-alpha 2a and ribavirin in the treatment of hepatitis C 49
Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF) 49
High mortality in COVID-19 patients with mild respiratory disease 49
Sofosbuvir Treatment in the Pre and Post Liver Transplantation Phase: The Sooner, the Better 48
A Review of the Treatment of Chronic Hepatitis C Virus Infection in Cirrhosis 48
Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside 48
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response 48
Estimating HCV disease burden - volume 3 (editorial) 47
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 47
Sofosbuvir for the treatment of chronic hepatitis C : between current evidence and future perspectives 46
Hepatorenal Syndrome and Novel Advances in its Management 46
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection 46
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials 46
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 46
Chronic hepatitis C: standard of care and perspective 45
Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics? 45
The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis 45
Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure 45
Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: Case study 45
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis 45
Will the benefits of treatment for chronic hepatitis C be retained in the interferon-free era? 45
Hepatitis C treatment in patients with kidney disease 45
Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation 44
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naive patients with genotype 1 chronic hepatitis C 44
Hepatitis C virus genotypes and patterns of peginterferon alfa-2b/ribavirin treatment failure in patients with cirrhosis : a single center study of 471 naïve patients 44
Lack of rapid virological response. predicts interferon-alpha 2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study 44
All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis 44
HCV genotype 3: An independent predictor of fibrosis progression in chronic hepatitis C 43
The Role Of Serum Alphafetoprotein Determination In HCV-Cirrhosis After Antiviral Treatment 43
Optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis C : more questions than answers 43
Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir. 43
Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and hepatocellular carcinoma-a composite scenario 43
Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response 43
De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis c (case study and literature review) 43
From current status to optimization of HCV treatment: Recommendations from an expert panel 43
Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19 43
Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: Effects on blood pressure control and mortality 43
The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy 42
Age Might Confound the Impact of the Transmembrane 6 Superfamily Member 2 E167K Polymorphism on Hepatic Fibrosis in Hepatitis C Virus-Infected Patients REPLY 42
Interferon in the treatment of chronic hepatitis C: a drug caught between past and future 42
Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage 42
Reply to: "The "pegylated" story continues - Perhaps because both ends (alpha 2a and alpha 2b) are true?" 42
Assessing long-term treatment efficacy in chronic hepatitis B and C : Between evidence and common sense 42
Increased risk of hepatocellular carcinoma in HCV (+) non responder cirrhotics with high liver cell proliferation 42
Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients 42
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission 42
Interferon-free oral therapy for hepatitis C : "faraway, so close!" 41
Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection 41
Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management 41
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection 41
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia 41
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65years with HCV genotype 1 cirrhosis 41
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? 41
Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: The plot thickens 40
Allelic inhibition of displacement activity: A simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms 40
Commentary : Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C 40
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1 40
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 40
Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report 40
Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era 40
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C 39
Treatment of chronic hepatitis C: can complexity pave the way towards elimination? 39
Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy 39
Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C 39
Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection 39
Daclatasvir for the treatment of chronic hepatitis C 39
Deciding on interferon-free treatment for chronic hepatitis C : Updating liver stiffness cut-off values to maximize benefit 39
Selection of resistant-associated variants to the NS5A inhibitor daclatasvir : revenge of the hepatitis C virus 39
Mediterranean diet and NAFLD: what we know and questions that still need to be answered. 38
EASL Recommendations on Treatment of Hepatitis C 2014 38
Treatment of patients with dual hepatitis B and C: a step in the right direction 38
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals 38
Evaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease 38
Global characterization of tumor infiltrate of Intrahepatic Cholangiocarcinoma by single cell sequencing 38
Prevalence and clinical significance of intrahepatic cholangiocellular carcinoma with radiological enhancement pattern mimicking hepatocellular carcinoma 38
A rapid point-of-care test for the diagnosis of HCV infection: tipping the balance to screening extension beyond high risk populations? 37
Second wave anti-HCV protease inhibitors: too little too late? 37
Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis 37
No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals 37
Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection 37
Hepatitis C virus post-exposure prophylaxis: A reasonable option in the era of pangenotypic direct-acting antivirals? 37
Acute tubular necrosis following interferon-based therapy for hepatitis C : case study with literature review 37
TACE with drug-eluting beads is effective for the maintenance of the milan-in status in patients with a small hepatocellular carcinoma 37
Role of liver biopsy in hepatocellular carcinoma 37
Totale 4401
Categoria #
all - tutte 48092
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48092

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202011 0000 00 00 00011
2020/20213079 22302716 8967 482213 53039913372
2021/20221714 801960361 2021 77223 129199409116
2022/20234726 678216460563 434410 16420 8903752640
Totale 9530